Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aequus Pharmaceuticals Inc (TSE:AQS)
TSXV:AQS
Holding TSE:AQS?
Track your performance easily
AQS Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.01 - C$0.05
Previous CloseC$0.01
Volume205.00K
Average Volume (3M)151.33K
Market Cap
C$1.72M
Enterprise ValueC$2.10M
Total Cash (Recent Filing)C$286.89K
Total Debt (Recent Filing)C$667.16K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 27, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding132,634,431
10 Day Avg. Volume38,101
30 Day Avg. Volume151,334
Standard Deviation0.24
R-Squared0.00009
Alpha-0.00805
Financial Highlights & Ratios
Price to Book (P/B)-0.38
Price to Sales (P/S)6.16
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Aequus Pharmaceuticals News
PremiumCompany Announcements
Aequus Pharmaceuticals Reports Strong Q2 Financials
PremiumCompany Announcements
Aequus Pharmaceuticals Celebrates Zimed® PF Sales Record
PremiumCompany Announcements
Aequus to Distribute Innovative Glaucoma Device
PremiumCompany Announcements
Aequus Reports Q1 Financials and ZIMED® PF Launch
PremiumCompany Announcements
Aequus Boosts Supply Amid Bimatoprost Shortage
PremiumCompany Announcements
Aequus Ramps Up Supply Amid Glaucoma Drug Shortage
PremiumPress Releases
Aequus Announces Zimed PF Now Available in CanadaOptions Prices
Currently, No data available
---
Ownership Overview
19.34%
Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
80.66% Public Companies and
Individual Investors
AQS FAQ
What was Aequus Pharmaceuticals Inc’s price range in the past 12 months?
Aequus Pharmaceuticals Inc lowest stock price was C$0.01 and its highest was C$0.05 in the past 12 months.
What is Aequus Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Aequus Pharmaceuticals Inc’s upcoming earnings report date?
Aequus Pharmaceuticals Inc’s upcoming earnings report date is Nov 27, 2024 which is in 68 days.
How were Aequus Pharmaceuticals Inc’s earnings last quarter?
Aequus Pharmaceuticals Inc released its earnings results on Aug 29, 2024. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.
Is Aequus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Aequus Pharmaceuticals Inc’s price is currently Overvalued.
Does Aequus Pharmaceuticals Inc pay dividends?
Aequus Pharmaceuticals Inc does not currently pay dividends.
What is Aequus Pharmaceuticals Inc’s EPS estimate?
Aequus Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aequus Pharmaceuticals Inc have?
Aequus Pharmaceuticals Inc has 132,634,430 shares outstanding.
What happened to Aequus Pharmaceuticals Inc’s price movement after its last earnings report?
Aequus Pharmaceuticals Inc reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aequus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in TSE:AQS
---
Aequus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.05%
Trailing 12-Months
Company Description
Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc is a Canada based specialty pharmaceutical company. The firm's operating segments are Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. Aequus is developing a pipeline of products in neurology and psychiatry. The company's launched and pipeline products are Tacrolimus IR, Vistitan, AQS1304, AQS1303, and others.
---
Technical Analysis
---